I hope the company posts the paper or transcript of the presentation. I can not get to Washington this weekend, I would have loved to attend the conference.
I have also recently asked the Micheal J Fox foundation if they have been aware of the work at Florey. I never got all the details on the efficacy shown in the primate studies with Duke. I am thrilled with the human trials because with humans, you can get patient feedback in a much more detailed manner.
Six months is still early, but if the lower dose initial safety study levels show some notable efficacy in this 6 month milestone, then they really have something going forward that could truly help people.
Best of luck to all. I know investors want to make money here, but the biggest reward would be the improvement in and longevity of the patients lives............
HS
News 
Market Data 
Discover 
